Fast track — ArticlesLong-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study
Introduction
Idiopathic restless legs syndrome is a common, chronic neurological disorder that often requires long-term therapy,1 particularly if symptoms are severe, frequent, and impair daily activities and quality of life.2, 3 The disease has a circadian pattern, with symptoms worsening in the evening and at night.4 Patients with restless legs syndrome have an urge to move their legs or arms during periods of rest and inactivity, which is frequently accompanied by unpleasant sensations in these limbs. These sensations are uncomfortable for the patient, and can include paraesthesia, itching, or pain. Sleep disruption is a major complaint and can result in chronic loss of sleep. Daytime symptoms are sometimes masked because movement, especially walking, provides almost immediate relief. As disease severity increases, additional daytime symptoms develop and daytime functioning can become impaired.4
Dopamine agonists are the first-line treatment for moderate-to-severe restless legs syndrome.5 However, their efficacy has been investigated only in short-term double-blind trials (12 weeks,6, 7, 8, 9 or 6 months10, 11, 12) and in open-label trials of up to 1 year in duration.13, 14, 15 Rotigotine is a non-ergot dopamine agonist that has been shown to be well tolerated and efficacious in patients with restless legs syndrome in placebo-controlled trials of up to 6 months.10, 12 Additionally, findings of a polysomnographic study showed benefits on sleep.16 Rotigotine is administered via a transdermal patch; continuous 24-h transdermal drug delivery maintains stable concentrations in plasma.17 The patch is replaced once daily in the morning. This treatment schedule might be particularly advantageous for patients who have daytime symptoms or fluctuations in the time of symptom onset.
To investigate the long-term safety, tolerability, and efficacy of rotigotine transdermal patch in patients with moderate-to-severe restless legs syndrome, we did a prospective 5-year open-label extension of a 6-week randomised trial.18 Findings of interim analyses suggest that rotigotine transdermal patch provides sustained relief from symptoms of restless legs syndrome with a good safety and tolerability profile at 1 year19 and 2 years20 of follow-up.
Additionally, we did a retrospective systematic analysis of study data to investigate the 5-year incidence of augmentation of restless legs syndrome with rotigotine therapy. Augmentation is defined as an increase in the severity of symptoms beyond baseline levels, and represents the main complication of long-term dopaminergic treatment.21 Previous studies have indicated that the incidence of augmentation with rotigotine is low during 6 months22 and 1 year23 of treatment.
Section snippets
Patients
Patients completing the 6-week treatment period in a phase 2b, randomised, double-blind, placebo-controlled, dose-finding trial (SP709, NCT00243217)18 were given the opportunity to enter a single-arm open-label extension study (SP710) after tapering of randomly assigned study treatment. The extension study was done between July 31, 2003, and April 15, 2009, in 33 hospital outpatient units, university centres, sleep centres, or private neurology clinics in three European countries (Austria,
Results
Of 310 patients who completed the double-blind trial, 295 entered the open-label extension study (figure 1). Five patients (2%) discontinued during the open-label titration period and 70 (24%) discontinued during the first year of follow-up. In total, 169 patients (57%) discontinued treatment before the end of maintenance, 31 (11%) because of lack of efficacy and 89 (30%) because of adverse events. 126 patients (43%) completed the maintenance period.
Patients had a long history of restless legs
Discussion
The findings of our study show that rotigotine transdermal patch is generally well tolerated with a good safety profile for up to 5 years of treatment (panel). Application site reactions were the main tolerability issue and mostly occurred during the first year of maintenance. Efficacy was sustained for up to 5 years at a level consistent with that attained in the initial 6-week double-blind study.18 Few patients required a dose increase, although the most frequently applied dose in 44% of
References (38)
- et al.
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health
Sleep Med
(2003) - et al.
The restless legs syndrome
Lancet Neurol
(2005) - et al.
Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial
Mayo Clin Proc
(2006) - et al.
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial
Lancet Neurol
(2008) - et al.
Open-label study of the long-term efficacy and safety of pramipexole in patients with restless legs syndrome (extension of the PRELUDE study)
Sleep Med
(2008) - et al.
A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome
Sleep Med
(2007) - et al.
Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study
Sleep Med
(2010) - et al.
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe
Sleep Med
(2008) - et al.
One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome
Sleep Med
(2008) - et al.
Dopaminergic augmentation of restless legs syndrome
Sleep Med Rev
(2010)
Validation of the augmentation severity rating scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome
Sleep Med
Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine–International Restless Legs Syndrome study group consensus conference at the Max Planck Institute
Sleep Med
High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease
Parkinsonism Relat Disord
Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome
Lancet Neurol
Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome
Sleep Med
Restless legs syndrome prevalence and impact: REST general population study
Arch Intern Med
Restless legs syndrome: pathophysiology, clinical presentation and management
Nat Rev Neurol
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice
Mov Disord
Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries
J Neurol Neurosurg Psychiatry
Cited by (114)
Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome
2022, Sleep Medicine ClinicsThe Management of Restless Legs Syndrome: An Updated Algorithm
2021, Mayo Clinic ProceedingsPharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome
2020, Sleep Medicine ClinicsTreatment of newly diagnosed restless legs syndrome
2019, Medecine du SommeilPharmacological treatments of augmentation in restless legs syndrome patients
2019, Advances in PharmacologyD3 receptor agonist efficacy in restless legs syndrome
2019, Advances in Pharmacology
- ‡
Members listed at end of paper